ARIMIDEX^™: A new oral, once-a-day aromatase inhibitor

Keyphrases

• Plasma Concentration 100%
• Once a Day 100%
• Aromatase Inhibitors 100%
• Daily Dose 66%
• Advanced Breast Cancer 66%
• Cortisol 33%
• Postmenopausal Women 33%
• Oral Administration 33%
• Breast Cancer Treatment 33%
• Safety Profile 33%
• Previous Treatment 33%
• 4-fold 33%
• Estradiol 33%
• Phase II Study 33%
• Breast Cancer 33%
• Start of Treatment 33%
• Clinically Significant 33%
• Breast Cancer Patients 33%
• Am(III) 33%
• Aldosterone 33%
• Increased Dose 33%
• Long-term Treatment 33%
• Pharmacology 33%
• Metastatic Disease 33%
• Pharmacodynamics 33%
• Pharmacokinetic Profile 33%
• Aromatase 33%
• Tumor Burden 33%
• Elimination Half-life 33%
• Pharmacokinetics-pharmacodynamics (PK-PD) 33%
• Steady-state Plasma Concentration 33%
• Systemic Treatment 33%
• Estradiol Level 33%
• Plasma Half-life 33%
• Treatment Burden 33%
• Maximum Degree 33%
• Steroid Hormone Biosynthesis 33%
• Single Administration 33%
• Suppressive Activity 33%
• Pharmacologic Effects 33%
• Aromatase Inhibition 33%
• ACTH Stimulation 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Breast Cancer 100%
• Aromatase Inhibitor 100%
• Diethylstilbestrol 50%
• Aromatase 50%
• Elimination 25%
• Metastasis 25%
• Neoplasm 25%
• Hydrocortisone 25%
• Pharmacodynamics 25%
• Aldosterone 25%
• Corticotropin 25%
• Systemic Treatment 25%
• Corticosteroid 25%